Literature DB >> 24938388

Posaconazole responsive cerebral aspergillosis in an immunocompetent adult.

Jonathan Richard Ellenbogen1, Mueez Waqar2, David W Denning3, Richard P D Cooke4, Derek W Skinner5, Tristram Lesser6, Mohsen Javadpour7.   

Abstract

Cerebral aspergillosis is a rare manifestation of invasive aspergillosis that usually affects immunocompromised patients. There are few treatment options for recurrent disease and experiences with immunocompetent patients are lacking. We report the clinical course of an immunocompetent patient with recurrent cerebral aspergillosis, following initial treatment with burr hole aspiration and voriconazole, who showed remarkable response to posaconazole. The patient remains clinically well with no evidence of recurrence on MRI 7 years following diagnosis. To our knowledge this is the first reported experience with posaconazole in an immunocompetent patient with cerebral aspergillosis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aspergillosis; Central nervous system; Immunocompetent; Posaconazole; Voriconazole

Mesh:

Substances:

Year:  2014        PMID: 24938388     DOI: 10.1016/j.jocn.2014.05.004

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Intracranial Aspergillosis in an Immunocompetent Young Woman.

Authors:  Prasan Kumar Panda; Sunil Kumar Mavidi; Naveet Wig; Ajay Garg; Aasma Nalwa; M C Sharma
Journal:  Mycopathologia       Date:  2017-01-04       Impact factor: 2.574

Review 2.  Intracranial aspergillosis in immunocompetent adult patients without risk factors: a systematic review.

Authors:  Kyoung Su Sung; Jaejoon Lim; Hun Ho Park
Journal:  Neurosurg Rev       Date:  2022-03-12       Impact factor: 3.042

3.  CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  M Schmidt-Hieber; G Silling; E Schalk; W Heinz; J Panse; O Penack; M Christopeit; D Buchheidt; U Meyding-Lamadé; S Hähnel; H H Wolf; M Ruhnke; S Schwartz; G Maschmeyer
Journal:  Ann Oncol       Date:  2016-04-06       Impact factor: 32.976

4.  Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.

Authors:  Frédéric-Antoine Dauchy; Mélanie Bonhivers; Nicolas Landrein; Denis Dacheux; Pierrette Courtois; Florian Lauruol; Sylvie Daulouède; Philippe Vincendeau; Derrick R Robinson
Journal:  PLoS Negl Trop Dis       Date:  2016-11-17

Review 5.  Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.

Authors:  Zorica Jović; Slobodan M Janković; Dejana Ružić Zečević; Dragan Milovanović; Srđan Stefanović; Marko Folić; Jasmina Milovanović; Marina Kostić
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.569

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.